Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379

Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research